Benzgalantamine

Brand names: Zunveyl · Active ingredient: Benzgalantamine

In short: ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

Forms & strengthsZUNVEYL delayed-release tablets are enteric coated and available in the following strengths of benzgalantamine: 5 mg white, round, and convex, debossed with "B05" in grey 10 mg purple, round, and convex, debossed with "B10" in grey 15 mg grey, round, and …
LabelAlpha Cognition, Inc.
Label updatedOct 08, 2026

What is Benzgalantamine used for?

ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

Benzgalantamine dosage

Dosage

The recommended starting dosage is 5 mg twice a day (10 mg/day) by mouth. Increase to initial maintenance dosage of 10 mg twice daily (20 mg/day) after a minimum of 4 weeks, based on clinical response and tolerability. Dosage may be increased to the maximum recommended dosage of 15 mg twice a day (30 mg/day) after a minimum of 4 weeks at 10 mg twice daily.

Administration

ZUNVEYL can be taken with or without food.

ZUNVEYL should not be taken with alcohol.

Swallow whole; do not split, crush or chew.

Ensure adequate fluid intake during treatment.

Interruption of Therapy

If therapy has been interrupted for more than three days, the patient should be restarted at the lowest dosage and the dosage escalated to the current dose.

No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh score of 5-6). In patients with moderate hepatic impairment (Child-Pugh score of 7-9), the dosage should generally not exceed 10 mg twice daily (20 mg/day). The use of ZUNVEYL in patients with severe hepatic impairment (Child-Pugh score of 10-15) is not recommended.

In patients with creatinine clearance of 9 to 59 mL/min, the dosage should generally not exceed 10 mg twice daily (20 mg/day). In patients with creatinine clearance less than 9 mL/min, the use of ZUNVEYL is not recommended.

How to take Benzgalantamine — instructions & advice from the label

Serious Skin Reactions

Advise patients and caregivers to discontinue ZUNVEYL and seek immediate medical attention at the first appearance of skin rash.

Administration Information

Instruct patients or caregivers about the recommended dosage and administration of ZUNVEYL delayed-release tablets, which should be administered twice daily with or without food.

Instruct patients to swallow ZUNVEYL whole and not to split, crush, or chew the tablets.

Advise patients and caregivers to ensure adequate fluid intake during treatment and that ZUNVEYL should not be taken with alcohol.

Active ingredient made in Taiwan.

Warnings & precautions

Do not take this medicine if: ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredient in ZUNVEYL. Serious skin reactions have occurred.

Serious skin reactions (e.g., Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of (ZUNVEYL) tablets. Inform patients and caregivers that the use of ZUNVEYL tablets should be discontinued at the first appearance of a skin rash, unless the rash is clearly not drug-related. If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.

ZUNVEYL, as a cholinesterase inhibitor, is likely to increase the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia.

Because of their pharmacological action, cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.

Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope (placebo 0.7% [2/286]; 4 mg twice daily 0.4% [3/692]; 8 mg twice daily 1.3% [7/552]; 12 mg twice daily 2.2% [6/273]).

Through their primary action, cholinomimetics, including ZUNVEYL, may be expected to increase gastric acid secretion because of increased cholinergic activity. …

Benzgalantamine side effects

The following serious adverse reactions are discussed in more detail elsewhere in the labeling:

Serious Skin Reactions

Cardiovascular Conditions

Gastrointestinal Conditions

Genitourinary Conditions

Neurological Conditions

Pulmonary Conditions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of ZUNVEYL has been established in studies of galantamine immediate-release tablets and galantamine extended-release capsules. Below is a display of the adverse reactions of galantamine in these studies.

Galantamine Extended-Release Capsules and Immediate-Release Tablets

The safety of the extended-release capsule and immediate-release tablet formulations of galantamine was evaluated in 3956 galantamine-treated patients who participated in 8 placebocontrolled clinical studies and 1454 patients in 5 open-label clinical studies with mild to moderate dementia of the Alzheimer's type. In clinical studies, the safety profile of once-daily treatment with extended-release galantamine was similar in frequency and nature to that seen with immediate-release galantamine. The information presented in this section was derived from pooled double-blind studies and from pooled open-label data. …

Drug interactions

Galantamine has the potential to interfere with the activity of anticholinergic medications.

A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.

About this medicine

ZUNVEYL (benzgalantamine) is a prodrug of galantamine, an acetylcholinesterase inhibitor . Benzgalantamine gluconate is known chemically as (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6- benzoate gluconate salt. It has an empirical formula of C30H37NO11and has a molecular weight of 587.61 (gluconate salt) and 391.46 (benzgalantamine). Benzgalantamine gluconate is a white to pale yellow powder and is soluble in water. Benzgalantamine has a pH of 5 to 6 and dissociation constant (pKa) of 7.0. It is slightly soluble in methanol and practically insoluble in acetone, acetonitrile and hexane. The structural formula for benzgalantamine gluconate is:

ZUNVEYL contains 5 mg, 10 mg, 15 mg benzgalantamine equivalent to 7.49 mg, 14.98 mg, and 22.47 mg benzgalantamine gluconate, respectively. ZUNVEYL delayed-release tablets are for oral use. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID af47bf67-1f07-4650-8064-24c38afc4656. Read the full official label on DailyMed.